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Reductions in plasma endocannabinoids following bariatric surgery 
in morbidly obese females with impaired glucose homeostasis:  
A non-randomized prospective study  
•  Endocannabinoids (ECs) are bioactive lipid mediators 
−  N-arachidonyl ethanolamine (AEA) 
−  N-palmitoyl ethanolamine (PEA) 
−  N-oleoyl ethanolamine (OEA)  
−  related N-acylethanolamine (NAE) derivatives  
−  2-arachidonyl glycerol (2-AG)  
•  Endocannabinoid system (ECS) plays a critical role in 
regulation of body weight and may have a role in 
aetiopathogenesis of Type 2 Diabetes (T2DM) 
•  Elevated circulating levels of AEA and 2-AG in obese 
people compared to non-obese controls of both genders 
•  Little information available on the effects of extreme weight 
loss associated with bariatric surgery in relation to the ECS 
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•  To examine gender differences and changes in circulating 
ECs in relation to bariatric surgery 
•  To examine the association between circulating ECs and 
markers of obesity, and insulin and glucose homeostasis pre- 
and post-bariatric surgery 
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•  Non-randomised prospective study  
•  20 participants undergoing bariatric surgery  
•  All participants either had T2DM, or impaired glucose regulation  
•  Fasting and 2-hour plasma glucose, lipids, insulin, C-peptide, 
measures of insulin sensitivity and plasma ECs were measured 
pre-operatively and 6 months post-operatively  
Table 2: Pre and post-operative gender differences in ECs 
References 
•  Gender differences exist in circulating levels of ECs in morbidly obese subjects 
•  Specific correlations exist between different ECs and markers of obesity, and insulin and glucose homeostasis pre-operatively 
† 
Whole group analysis (Table 1) 
•  Significant reduction in weight, HbA1c, 2- hour plasma glucose, and fasting insulin, and increase in hepatic insulin clearance at 6 months 
•  No significant changes in the AEA, OEA, PEA and 2-AG post-operatively  
Gender-specific analysis (Table 2)   
•  Differences in AEA, OEA and PEA  between males and females pre-operatively 
•  Reductions in AEA & PEA in females post-operatively 
Correlations between circulating ECs and markers of obesity, insulin and glucose homeostasis pre and post-operatively (Table 3) 
Measurement Preoperative (n=20) Postoperative (n=20) P  
Weight (kg) 160.2 (44.2) 124.8 (29.4) <0.001 
BMI (kg/m2) 57.3 (14.1) 45.4 (10.1) <0.001 
HbA1c (%) 7.2 (1.5) 
       
6.1 (1.3) 0.02 
FPG (mmol/L) 7.8 (3.3) 6.0 (3.1) 0.13 
2-hr PG (mmol/L) 12.7 (4.9) 8.3 (5.9) 0.01 
Fasting insulin (IU/mL) 27.9 (16.2) 11.4 (6.7) 0.002 
Fasting C-peptide (ng/mL) 3.6 (1.5) 2.9 (1.5) 0.10 
HOMA %S 305.8 (208.3) 617.5 (492.5) 0.03 
HOMA- IR 0.4667 (0.3016) 0.3600 (0.4154) 0.32 
C-pep: Insulin ratio 0.1744 (0.0996) 0.2741 (0.1246) 0.001 
AEA (pmol/mL)* 0.21 (0.04) 0.19 (0.04) 0.33 
OEA (pmol/mL)* 1.05 (0.13) 0.93 (0.18) 0.25 
PEA (pmol/mL)* 0.83 (0.09) 0.74 (0.09) 0.10 
2-AG (pmol/mL)* 5.0 (1.55) 4.2 (1.40) 0.14 
 * Geometric mean and approximate standard deviation shown for log transformed data  
Measurement	   Preoperative	    	   Postoperative	    	  
 	   Females	   Males	   P 	   Females	   Males	   P 	  
AEA (pmol/mL)*	   0.297 (0.042)	   0.147 (0.021)	   <0.001	   0.209 (0.049)†	   0.165 (0.033)	   0.30	  
OEA (pmol/mL)*	   1.263 (0.125)	   0.869 (0.085)	   0.002	   0.947 (0.232)	   0.912 (0.127)	   0.86	  
PEA (pmol/mL)*	   0.964 (0.096)	   0.720 (0.054)	   0.005	   0.759 (0.110) ††	   0.713 (0.084)	   0.67	  
2-AG (pmol/mL)*	   5.163 (1.831)	   4.019 (2.184)	   0.43	   5.156 (2.086)	   3.249 (0.840)	   0.51	  
*Geometric and approx SD shown. Log transformed. 
†P=0.02, Preoperative v 6 months postoperatively  ††P=0.007, Preoperative v 6 months postoperatively 
 
Variable AEA OEA PEA 2-AG 
Weight     
0 month 0.10 (0.68) 0.49 (0.03) 0.36 (0.12) 0.20 (0.45) 
6 months 0.01 (0.96) 0.01 (0.97) -0.23 (0.35) -0.16 (0.53) 
Waist     
0 month 0.10 (0.68) 0.52 (0.02) 0.40 (0.08) 0.26 (0.33) 
6 months -0.13 (0.62) -0.04 (0.86) -0.28 (0.25) 0.11 (0.70) 
Fasting glucose     
0 month 0.15 (0.55) 0.05 (0.84) 0.09 (0.71) -0.59 (0.04) 
6 months 0.54 (0.05) 0.11 (0.62) 0.18 (0.46) -0.09 (0.75) 
2-hour glucose     
0 month 0.55 (0.01) 0.11 (0.65) 0.17 (0.47) 0.003 (1.00) 
6 months -0.02 (0.94) -0.24 (0.33) -0.13 (0.60) -0.42 (0.10) 
Fasting insulin     
1 month 0.28 (0.26) 0.49 (0.04) 0.49 (0.04) 0.18 (0.54) 
6 months -0.03 (0.89) 0.06 (0.81) 0.08 (0.76) -0.19 (0.49) 
HOMA S%     
1 month -0.71 (0.002) -0.34 (0.18) -0.47 (0.06) 0.16 (0.57) 
6 months -0.35 (0.16) -0.25 (0.33) -0.33 (0.18) -0.21 (0.44) 
HOMA- IR     
0 month 0.61 (0.009) 0.48 (0.05) 0.53 (0.03) 0.27 (0.32) 
6 months 0.40 (0.1) 0.28 (0.27) 0.25 (0.31) 0.38 (0.15) 
Systolic BP     
0 month 0.40 (0.09) 0.11 (0.66) 0.25 (0.30) -0.01(1.0) 
6 month -0.13 (0.61) -0.27 (0.26) -0.06 (0.81) -0.07 (0.78) 
Diastolic BP     
0 month 0.48 (0.04) 0.01 (0.96) 0.14 (0.56) -0.52 (0.04) 
6 months -0.06 (0.83) -0.08 (0.76) 0.08 (0.74) -0.23 (0.38) 
LDL-C     
0 month 0.15 (0.54) 0.15 (0.52) 0.44 (0.04) -0.02 (0.94) 
6 months -0.27 (0.27) -0.26 (0.28) -0.04 (0.87) 0.13 (0.62) 
HDL-C     
0 month -0.21 (0.37) -0.12 (0.53) -0.31 (0.18) -0.73 (0.001) 
6 months -0.32 (0.18) 0.18 (0.45) 0.28 (0.25) 0.03 (0.91) 
2-AG     
0 month 0.08 (0.76)    
6 months -0.01 (0.98)    
OEA     
0 month 0.52 (0.02)    
6 months 0.60 (0.005)    
PEA     
0 month 0.71 (<0.001)    
6 months 0.61 (0.005)    
r-values with the P-values in brackets. Significant correlations in bold. 
Table 3: Correlations between ECs and markers of 
obesity, and insulin and glucose homeostasis 
